Short answer
OptimizeRx Corp (OPRX) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). Q2 2026 results for quarter ended June 30, 2026.
OptimizeRx Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release issued August 12, 2026
- Detailed financial results and management commentary in Exhibit 99.1
Item 5.02 · Departure/Election of Directors or Officers
- CFO Edward Stelmakh departs December 31, 2026 after 12 months of advisory service, creating a planned finance leadership transition
- Successor Andrew D’Silva brings internal continuity as CFO from January 1, 2027, with prior finance strategy and investor relations experience
- D’Silva receives $375,000 salary and 50% bonus target, plus one-timesalary severance and target bonus if terminated without cause
- Chief Accounting Officer Heather Favazza assumes expanded role January 1, 2027, supporting continuity in reporting and internal controls
- Stelmakh receives $450,000 salary continuation, $247,500 bonus payment, benefits reimbursement, and continued equity vesting during advisory term
Item 7.01 · Regulation FD Disclosure
- CFO & Strategy Officer Stelmakh departing effective December 31, 2026
- D’Silva appointed Chief Financial Officer effective January 1, 2027
- Favazza appointed Chief Accounting Officer effective January 1, 2027
- CFO succession creates execution and reporting continuity considerations for investors
Item EX-99.1 · Exhibit EX-99.2
- Andy D’Silva succeeds Ed Stelmakh as CFO effective January 1, 2027
- Heather Favazza becomes Chief Accounting Officer on January 1, 2027 after eight years as Corporate Controller
- Stelmakh remains Chief Financial & Strategy Officer through December 31, 2026 and Strategic Advisor through 2027
- Internal succession preserves finance continuity, with strategy and financial-growth plans unchanged
- D’Silva brings experience in capital allocation, investor relations, corporate development, and long-range planning
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other OptimizeRx Corp 8-K filings
Get the next OPRX 8-K as it lands
Follow OPRX for push alerts, or ask the research agent what this filing means.